WTG to launch ‘Early Drug Development Summit’ in Berlin

With its 15 years conference production and management experience, WTG introduces a leading pharma event: "Early Drug Development Summit" in December 3^rd-4^th 2012 in Berlin, Germany.

The Early Drug Development Summit brings early drug developers together to discuss maximising drug investments, toxicology, safety and biomarkers.

We're pleased to announce that Dr.Lucette Doessegger, Global Head of Translational Safety Medicine at Roche Switzerland, will be sharing her 10 years of industry experience on early drug development at the Early Drug Development Summit on Day 2, 4^th December 2012 at 09:15 - 10:00 in Hotel Palace Berlin, Germany.

Dr. Doessegger will discuss "Using Translational Medicines in Early Drug Development", which will cover:

• Designing risk management protocols to understand the mechanism of action and implement safety measurements
• Using translational safety medicine to measure signalling before it reaches clinical trials
• Efficiently determining the impact of toxicity effects on specific populations

Confirmed speakers and their presentations include:

• Dr Andy Parsons, VP Preclinical Development, GSK UK

Developing Business Frameworks for the Successful Co-creation of Value

• Peter Theil, Head of Early Development PKPD, UCB Belgium

Pre-IND PK/PD Characterization of Small Molecule Drugs and Biotherapeutics to Increase the Probability of Success of Drug Development

• Stefan Proniuk, VP Development, Arno Therapeutics US

Reducing Development Timelines to Bring Products to Market Faster

• Ian Wilson, Senior Principal Scientist, AstraZeneca UK

Successfully Identifying Human Drug Metabolites for Toxicity Testing

• Frederik Deroose, Director, Global Business Office Integrator, Jansenn Belgium

Successfully Using Virtual Outsourcing for Early Drug Development

• Prof Jürgen Borlack, Head of Toxicology, Hannover University Germany